Global demand for hunter syndrome treatment market was valued at approximately USD 927.9 million in 2019, and is expected to generate revenue of around USD 1,601.6 million by end of 2026, growing at a CAGR of around 8.2% between 2020 and 2026.
The report covers forecast and analysis for the hunter syndrome treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with forecast from 2020 to 2026 based on revenue (USD Million). The study includes drivers and restraints for the hunter syndrome treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hunter syndrome treatment market on a global as well as regional level.
In order to give the users of this report a comprehensive view on the hunter syndrome treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the hunter syndrome treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new indication launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the hunter syndrome treatment market on global and regional basis.
The study provides a crucial view on the hunter syndrome treatment by segmenting the market based on treatment and region. All the segments of hunter syndrome treatment market have been analyzed based on present and future trends and the market is estimated from 2016 to 2026.
The global demand for hunter syndrome treatment market is driven by expected approval of new therapies, growing research and development activities, and extended life expectancy. However, lack of awareness and high cost may act as restraining factors for the market growth in the coming years. Increasing collaboration and technological advancements are projected to bring new growth avenues for market players during the forecast timeframe.
The hunter syndrome treatment market has been divided into treatment and region. Based on treatment, global hunter syndrome treatment market is segmented into Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and others. Market was dominated by Enzyme Replacement Therapy (ERT) segment in 2019 and is projected to retain its dominance over the forecast timeframe.
North America held largest revenue share of the global hunter syndrome treatment market in 2018. This large share is attributed to government funding, growing awareness and presence of key players in this region. Europe was second leading regional market in terms of revenue. Availability of developed infrastructure, increasing geriatric population, and growing awareness are major factors that support market growth in this region. Asia Pacific region is projected to be rapidly growing regional market for hunter syndrome treatment. Increasing chronic disease prevalence and geriatric population base, economic development, improvement of healthcare infrastructure, growing awareness are major factors attributing to the swift growth in this region. Moderate growth is projected in Latin America region over the forecast period. Middle East and Africa will witness sluggish growth in the coming years.
Major players in hunter syndrome treatment market are GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc., JCR Pharmaceuticals Co Ltd., Sangamo Therapeutics, Inc., Inventiva S.A., ArmaGen Inc, Esteve, Bioasis Technologies Inc., and Denali Therapeutics Inc among others.
The report segment of global hunter syndrome treatment market as follows:
Global Hunter Syndrome Treatment Market: Treatment
Global Hunter Syndrome Treatment Market: By Region